Pentoxifylline protects against loss of function and renal interstitial fibrosis in chronic experimental partial ureteral obstruction

Ma, Hongyang; Lee, Steven; Yang, Yan; Bedi, Puneet; Chou, Shyan–Yih

doi:10.1016/j.pathophys.2018.08.004

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As PTX has been proven to possess anti-inflammatory effects, i.e., decreasing TNF-α, IL-6, and IL-1 plasma levels, as well the ability to decrease ROS production, and it has been widely evaluated in pre-clinical trials considering the treatment and prevention of various types of fibrosis. In animal models, PTX has shown efficacy in the prevention of renal interstitial fibrosis via inhibition of connective tissue growth factors and, thus, the prevention of extracellular matrix overproduction [42,43]. PTX-tocopherol combination treatment has been shown to reduce collagen type I and III depositions in the ECM in radiationinduced heart fibrosis using a rat model [44].…”

Section: Pulmonary Fibrosismentioning

confidence: 99%

Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm

Feret

Nalewajska

Wojczyński

et al. 2021

JCM

View full text Add to dashboard Cite

The outburst of inflammatory response and hypercoagulability are among the factors contributing to increased mortality in severe COVID-19 cases. Pentoxifylline (PTX), a xanthine-derived drug registered for the treatment of vascular claudication, has been reported to display broad-spectrum anti-inflammatory and immunomodulatory properties via adenosine A2A receptor (A2AR)-related mechanisms, in parallel to its rheological actions. Prior studies have indicated the efficacy of PTX in the treatment of various pulmonary diseases, including the management of acute respiratory distress syndrome of infectious causes. Therefore, PTX has been proposed to have potential benefits in the treatment of SARS-CoV-2 symptoms, as well as its complications. The aim of this review is to discuss available knowledge regarding the role of PTX as a complementary therapeutic in SARS-CoV-2.

show abstract

Section: Pulmonary Fibrosismentioning

confidence: 99%